Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada.
about
Platinum versus non-platinum chemotherapy regimens for small cell lung cancerPlatinum versus non-platinum chemotherapy regimens for small cell lung cancerPhase II trial of etoposide and cisplatin for refractory small cell lung cancer: a Cancer and Leukemia Group B Study.Prolonged, alternating chemotherapy for extensive small cell lung cancer. A Southwest oncology Group study.A phase II study of carboplatin and prolonged administration of oral etoposide in patients with small-cell lung cancer.Treatment of small-cell lung cancer.Extensive stage small cell lung cancer.Extrapulmonary and pulmonary small-cell carcinoma: tumor biology, therapy, and outcome.Current approaches to small cell lung cancer.Lung cancer: a review of current therapeutic modalities.Extensive-stage small-cell lung cancer.Chemotherapy for small cell lung cancer: a comprehensive reviewChemotherapy for urothelial tract malignancies: breaking the deadlock.Progress in treatment of small-cell lung cancer: role of CPT-11.Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.Effect of alternating combination chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, cisplatin, and etoposide for small cell lung cancer on hematopoietic progenitors in the peripheral bloodCMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.Does the substitution of cisplatin in a standard four drug regimen improve survival in small cell carcinoma of the lung? A comparison of two chemotherapy regimens.Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: results at 8 years (Pronacam 85)VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group.Lung cancer in the 1990s.Therapeutic resistance in lung cancer.Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent.Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer.Current status of etoposide in the management of small cell lung cancer.Etoposide. Current and future status.Update on new drugs in small cell lung cancer.Management of small cell lung cancer: recent developments for optimal care.Medical treatment of small cell lung cancer: state of the art and new development.Chemotherapy in lung cancer.Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.Small-cell lung cancer: an overview of issues in therapy.Semiparametric Bayesian survival analysis using models with log-linear medianA phase II study of weekly alternating chemotherapy in extensive-stage small cell lung cancer.A pilot study of intensive weekly chemotherapy for extensive disease small-cell lung carcinoma.Efficacy of two different platinum- or anthracycline-containing chemotherapy regimens for the treatment of small cell lung cancer.Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.CANADIAN CANCER RISK MANAGEMENT MODEL: EVALUATION OF CANCER CONTROLThe evaluation of cancer control interventions in lung cancer using the Canadian Cancer Risk Management Model
P2860
Q24188039-4257F30A-BEB8-4BED-A89F-BC56DF8F74C6Q24241071-A90C7F87-E2E9-4C49-845D-D9917348FCFCQ33395104-FA7AB018-579C-4641-AFD0-DAF76EA3A786Q33494029-0C1C5C4D-8EC2-49C6-A377-0538FBED9C3AQ33501822-8F91EC55-9450-4479-AD17-902E72D744C3Q33617197-BC6E5B18-B085-4B01-81D5-55706F5FFA02Q34678500-3F6829A1-766B-486D-AB6F-4D2AD55878B3Q35225021-FEC80C15-1D01-452E-B998-8BFEDDC2B4D6Q35227186-B12B89E8-03B4-44D0-B72E-5A580E2534E9Q35232728-2C39F965-B15D-4713-A8F6-CE6F5182F5C4Q35543185-D0253B9C-871B-4CA1-8BE9-A6A8B7DCD5F3Q35569379-7211AA58-9336-4EAF-BC7E-DE8B48C5261CQ35585559-A349C4E3-B103-4D2C-8071-76BBF0AA0B54Q35608220-665CCB43-476B-411A-A80D-EE2104F5D7E0Q35825822-4927C30C-7D95-46EF-8CC4-E8791E93AD8BQ35976381-1F542EBA-EF7C-4128-ADA2-B54C0E2CD3C5Q36081039-02B5FD9F-61BC-4163-87CB-567E77806EB6Q36081297-6D5A2D8D-CF74-438A-B47A-E26138AE706BQ36240882-D9F34FF1-851F-40C8-9FDF-9D4358ABD65FQ36430928-2FB200CB-1825-46A6-9D3B-1361B0987B99Q36466674-FD3FAE4A-43FB-4A10-910A-2230BADFE12AQ36520328-66A4E450-DDCA-4EF1-9C4B-733C77030154Q36609767-78D1A347-AA2B-48FC-A2D2-A50F5F697E2BQ36641834-BC838DC7-93F2-4DAA-A99B-2360906D43D5Q36858092-CFC08892-1581-40C9-8C17-32C5587012ECQ37155323-7C1C5E01-D931-4BA7-A97F-56F74B6D293AQ37619406-6EFDBC32-FACB-4FB1-A27E-02D7999A4D9BQ37851992-32CA2FE5-2891-45FC-BF38-2939FC0E499AQ37987205-9F4D73BB-3B89-47F8-9E25-3EE571CE7B5AQ38125489-2BD35035-92A5-4FE4-910E-31ECCED15441Q38316472-B3CB5EB0-6712-433E-8A44-9E64C05A0B0DQ39016544-62693BBE-8164-40D6-86D1-6616D4EC1A87Q40853728-AC34D7AC-A255-43F6-8191-00CAC3E8AE43Q41404316-219F0172-05B1-44C8-ACD5-896751F88971Q43598705-63897DF2-B99C-40E0-A008-3D6EAFB7F97BQ44895952-B440BD61-DD91-4445-8EF8-01F68EB726ADQ46514203-B3F92C30-720D-48A4-B918-69942D70426CQ53148481-F2C86AA7-8798-4F2E-B506-BA1E16FCC88CQ58287522-495B0CC5-9A20-4178-8493-A2C8AC8E9F3DQ58287526-E2ED3600-50D4-4EAF-B627-EB29B4B450AB
P2860
Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh-hant
name
Superiority of alternating non ...... al Cancer Institute of Canada.
@en
Superiority of alternating non ...... al Cancer Institute of Canada.
@nl
type
label
Superiority of alternating non ...... al Cancer Institute of Canada.
@en
Superiority of alternating non ...... al Cancer Institute of Canada.
@nl
prefLabel
Superiority of alternating non ...... al Cancer Institute of Canada.
@en
Superiority of alternating non ...... al Cancer Institute of Canada.
@nl
P2093
P1476
Superiority of alternating non ...... al Cancer Institute of Canada.
@en
P2093
MacDonald A
Shepherd FA
P304
P356
10.7326/0003-4819-107-4-451
P407
P577
1987-10-01T00:00:00Z